Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11
Original Research
![Noteworthy comment: This study assessed different methods to determine whether high ICERs (incremental cost-effectiveness ratio) are caused by high drug costs, high ‘background costs’ or a combination of both and how different approaches can alter the impact of background costs on the ICER where the marginal cost-effectiveness ratio is close to, or above, the cost-effectiveness threshold.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
7,012 | Dovepress* | 5,917+ | 1,525 | 7,442 | |
PubMed Central* | 1,095 | 220 | 1,315 | ||
Totals | 7,012 | 1,745 | 8,757 | ||
*Since 3 May 2019 |
View citations on PubMed Central and Google Scholar